Read more about ACB’s extensive work in GM and biosafety

More poisoning of South Africa’s staple food given the go-ahead: 2,4-D GM maize varieties approved

Press release

The African Centre for Biodiversity (ACB) is extremely alarmed to learn that three genetically modified maize varieties developed by Corteva (new name of the Dow-DuPont merged entity) to withstand the application of the dangerous 2,4-D herbicide have been approved for general release by the Executive Council: GMO Act. This poses a grave threat to the health of food consumers, farm workers and the environment.

Resounding no to Monsanto’s ‘bogus’ GM drought tolerant maize

Press release

 

Resounding no to Monsanto’s ‘bogus’ GM drought tolerant maize: South Africa’s Minister, Appeal Board and Biosafety Authority Reject Monsanto’s GM seeds

Johannesburg, South Africa, 4 October 2019

After more than 10 years of battling Monsanto’s ‘bogus’ drought tolerant maize project, the African Centre for Biodiversity (ACB) welcomes the decision by the Minister of Agriculture, Ms. Thoko Didiza, upholding of both the decision by the Executive Council: GMO Act and the Appeal Board to reject Monsanto’s application for the commercial cultivation of its triple stacked ‘drought-tolerant’ GM maize seed.

AFRICANS REFUSE TO BE CHEMICAL DUMPING GROUND

Press release

Civil society organisations and citizens across Africa are calling upon their governments to issue an immediate ban on all use of glyphosate and glyphosate-based herbicides (GBHs).

Launched by the Alliance for Food Sovereignty in Africa (AFSA) and the African Centre for Biodiversity (ACB), the #BanGlyphosateAfrica campaign has been endorsed by African organisations representing millions of African citizens. Governments across the continent are being inundated with messages, letters and petitions demanding that they protect their citizens with an immediate ban.

Globally, glyphosate and GBHs have contaminated all spheres of our environment and food systems, kicking off one of the world’s biggest health crises. Chronic diseases have increased in tandem with GBH use globally, as recent court cases in the USA have shown.